Hikma launches midazolam injection in prefilled syringe form

Hikma is introducing midazolam injection in 2mg/2ml and 10mg/2ml doses.

 The product has been launched in the U.S. in a prefilled syringe form and is indicated for:

• Intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia;
• Intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other CNS depressants;
• Intravenously for induction of general anesthesia, before administration of other anesthetic agents. With the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. Intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); and

[Read more: Hikma intros Kloxxado]

• Continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting.

Midazolam injection, 2mg/2ml and 10mg/2ml, had a market value of approximately $20 million for the 12 months ending February 2024, per IQVIA.